+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating how well intranasal esketamine works alongside standard care to quickly reduce symptoms of major depressive disorder MDD in adolescents with acute suicidal thoughts or behaviors. The study compares esketamine plus comprehensive standard care to a psychoactive placebo plus standard care to understand its effectiveness and safety in this population. Participants will be randomly assigned to one of two groups receiving treatment twice weekly for 4 weeks. One group receives intranasal esketamine starting at 84 mg, possibly reduced to 56 mg based on investigator judgment, along with oral placebo. The other group receives oral midazolam and intranasal placebo following a similar dosing schedule. The study allows dose flexibility between 56 mg and 84 mg for esketamine during treatment. During the study, participants will be monitored through various assessments including depression rating scales and measures of suicidality at baseline, 24 hours after the first dose, and throughout the 25-day treatment period. Researchers will evaluate changes in depressive symptoms, suicidality severity, and quality of life. Safety and adherence will be carefully observed, with the study continuing until primary outcome evaluation and completion by 2031.

Age: 12Years - 17YearsAll GendersPhase 3
49 locations
O

Actively Recruiting

Researchers are evaluating the effects and safety of two different doses of rilzabrutinib in adults with Graves disease, including those with and without Graves orbitopathy. This Phase 2, randomized, open-label study aims to better understand how rilzabrutinib impacts thyroid hormone levels in this population. The study is sponsored by Sanofi and involves a parallel group design with two treatment arms. Participants will receive either rilzabrutinib dose 1 or rilzabrutinib dose 2, both administered orally as tablets. The study includes a screening period lasting up to 4 weeks, followed by a treatment period of up to 16 weeks during which participants will take the assigned dose. After treatment, there is a 4-week follow-up period to monitor safety and treatment effects. Throughout the study, participants may have up to 13 visits. Participants will undergo assessments including measurements of thyroid hormone levels such as free thyroxine FT4 and free triiodothyronine FT3 at baseline and Week 16. Safety is monitored by tracking adverse events throughout the study and follow-up period. Researchers will analyze changes in hormone levels and the proportion of participants achieving normal thyroid levels. The total participation duration is approximately 24 weeks including screening, treatment, and follow-up.

Age: 18Years - 75YearsAll GendersPhase 2
24 locations
S

Actively Recruiting

This research aims to find simple external body landmarks that can reliably predict the correct depth for inserting an esophageal probe. Accurate placement in the lower third of the esophagus is important for precise core temperature monitoring. The study focuses on adult ICU patients who need transesophageal echocardiography TEE as part of their clinical care. The Institute of Mountain Emergency Medicine is sponsoring this observational study. Participants will undergo clinically needed transesophageal echocardiography, which will be used as the gold standard to confirm correct esophageal probe placement. During the procedure, researchers will measure several external anatomical points to predict insertion depth and compare these predictions with TEE-confirmed probe positions. The study will analyze how well the landmark-based method agrees with the TEE standard. Throughout the study, adult ICU patients will be evaluated during their routine TEE procedure. Researchers will collect anatomical measurements and confirm probe positions to assess accuracy. The main outcome is the agreement between the predicted insertion depth and the actual depth confirmed by TEE. The study will monitor results during the procedure period, supporting better methods for esophageal temperature monitoring in critical care.

All AgesAll Genders
1 location
E

Actively Recruiting

This research aims to evaluate whether acral cryotherapy can reduce the incidence and severity of chemotherapy-induced peripheral neuropathy CIPN in female breast cancer patients receiving weekly paclitaxel-based chemotherapy. CIPN is a common side effect caused by nerve damage during chemotherapy, which can affect quality of life and lead to treatment changes or stopping treatment. The study compares patients receiving cryotherapy with those receiving standard care without cryotherapy. Participants in the cryotherapy group will use the Hilotherm Chemocare device that delivers continuous-flow cold at 15C to the hands and feet. This cooling starts 15 minutes before chemotherapy infusion, continues during the infusion, and lasts 15 minutes after. The control group will receive standard care without cryotherapy. The study involves randomized assignment to either group. During chemotherapy and for one year after completing treatment, participants will undergo repeated assessments including neurological exams, nerve conduction studies, patient questionnaires on quality of life, and blood tests. Additional blood samples will be collected at two time points to analyze biomarkers of nerve damage. The main outcome measured is the change in neuropathy score from before treatment to six months after chemotherapy ends.

Age: 18Years - 90YearsFEMALEPhase Not Applicable
4 locations
P

Actively Recruiting

Acute respiratory distress syndrome ARDS is a serious lung condition causing inflammation and fluid buildup, leading to severe breathing problems and high mortality in intensive care units worldwide. Despite many clinical trials, no specific drug has yet proven effective in treating ARDS. The study aims to evaluate the anti-fibrotic medication Pirfenidone, previously used for idiopathic pulmonary fibrosis, to see if it can prevent lung fibrosis and improve outcomes in ARDS patients. Participants will be randomly assigned to receive either Pirfenidone or a placebo. Pirfenidone dosing starts at 801 mg per day for the first week, increases to 1602 mg per day for the second week, and then to 2403 mg per day until ICU discharge. The medication or placebo is given through a nasogastric tube in three divided doses daily. This is a phase 3 randomized controlled trial conducted across multiple centers. Throughout the study, researchers will monitor the number of days participants are free from ventilators within 28 days, length of ICU stay, lung imaging changes, mortality rates, lung function tests, heart function, and quality of life up to one year. Samples from the lungs will also be collected to study inflammation. Safety and any adverse effects will be closely tracked. The study will continue until December 2026.

Age: 18Years +All GendersPhase 3
17 locations